8-KShareholder Matters

ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (Apr 28, 2014)

Filed April 28, 2014For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on April 28, 2014, reporting on the outcomes of its Annual Meeting of Shareholders held on April 25, 2014. The primary focus of the filing is the voting results on several key proposals. Investors can take comfort in the overwhelming support for the re-election of the entire Board of Directors and the ratification of Ernst & Young LLP as the company's independent auditor. Additionally, shareholders provided a positive, albeit advisory, vote of confidence in the compensation of the company's named executive officers. The filing also indicates a strong rejection of two shareholder proposals concerning genetically engineered ingredients and lobbying disclosures. These outcomes suggest that the current board and executive compensation practices are aligned with the views of a significant majority of Abbott's shareholders, and the company is not currently inclined to adopt the specific policies requested by the proponents of the rejected proposals.

Key Highlights

  • 1Abbott Laboratories' shareholders overwhelmingly re-elected the entire Board of Directors, with all nominees receiving substantial support.
  • 2The appointment of Ernst & Young LLP as Abbott's independent auditor for the fiscal year was ratified by a significant majority of shareholders.
  • 3Shareholders provided an advisory vote of approval for the compensation of Abbott's named executive officers, with 94.71% of cast votes in favor.
  • 4A shareholder proposal requesting the identification and labeling of genetically engineered ingredients was rejected, with only 5.25% of cast votes in favor.
  • 5Another shareholder proposal seeking detailed disclosures on the company's lobbying policies and expenditures was also rejected, receiving only 6.25% of cast votes in favor.
  • 6A shareholder proposal concerning 'Incentive Compensation - Compliance Costs' was withdrawn prior to the meeting and was not voted upon.

Frequently Asked Questions

The main outcomes were the re-election of all board members, ratification of the auditor (Ernst & Young LLP), advisory approval of executive compensation, and rejection of shareholder proposals regarding genetically engineered ingredient labeling and lobbying disclosures.

All nominated directors received substantial support, with 'Votes For' ranging from approximately 1.05 billion to 1.1 billion shares, against 'Votes Withheld' and a consistent number of broker non-votes.

No, both shareholder proposals were rejected. The proposal on genetically engineered ingredients received only 5.25% of cast votes in favor, and the proposal on lobbying disclosures received 6.26% of cast votes in favor.

No, the shareholder vote on the compensation of named executive officers is advisory and non-binding. However, the strong approval (94.71% of cast votes) indicates shareholder support for the company's compensation practices.